All In Biotech

Drug Trial Radar · NCT06012240

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Oct 11, 2023

Primary completion

Apr 2030

Study completion Apr 2030

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 63 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA. Upadacitinib is an approved drug being investigated for the treatment of AA. In Study 1 and Study 2 and Study 4 Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo. In Study 1 and Study 2 and Study 4 Period B, participants originally randomized to upadacitinib dose group in Period A will continue their same treatment in Period B. Participants originally randomized to Placebo in Period A will either remain on placebo in Period B, or be randomized in 1 of 2 groups, based off of their Severity of Alopecia Tool (SALT) score. Participants who complete Study 1, Study 2 or Study 4, can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. Around 1500 participants with severe AA will be enrolled in the study at approximately 280 sites worldwide. Participants will receive oral tablets of either upadacitinib or placebo once daily for up to 160 weeks with the potential of being re-randomized into a different treatment group at Weeks 24 and 52. Participants will be followed up for up to 30 days after last study drug dose. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Alopecia Areata

Interventions

  • UpadacitinibDrug

    Oral Tablets

  • PlaceboDrug

    Oral Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20Time frame: Week 24
  2. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 164 weeks

Locations

272 sites in 28 countries. Site status is shown where the registry gives one.

  • Total Skin and Beauty Dermatology Center /ID# 259539

    Birmingham, Alabama · Active not recruiting

  • Duplicate_Advanced Research Associates - Glendale /ID# 259108

    Glendale, Arizona · Completed

  • Southwest Skin Specialists /ID# 258234

    Phoenix, Arizona · Completed

  • Alliance Dermatology and Mohs Center /ID# 258111

    Phoenix, Arizona · Active not recruiting

  • Johnson Dermatology Clinic /ID# 259103

    Fort Smith, Arkansas · Active not recruiting

  • Duplicate_JOSEPH RAOOF MD,INC /ID# 258031

    Encino, California · Completed

  • First Oc Dermatology /ID# 259220

    Fountain Valley, California · Recruiting

  • University of California Irvine /ID# 259096

    Irvine, California · Active not recruiting

  • Dermatology Research Associates /ID# 258033

    Los Angeles, California · Recruiting

  • Stanford University School of Medicine - Redwood City /ID# 259542

    Redwood City, California · Completed

  • Integrative Skin Science and Research /ID# 258114

    Sacramento, California · Recruiting

  • University of California Davis Health /ID# 258112

    Sacramento, California · Recruiting

  • Clinical Trials Research Institute /ID# 258021

    Thousand Oaks, California · Recruiting

  • Skin Care Research Boca Raton /ID# 258012

    Boca Raton, Florida · Recruiting

  • Apex Clinical Trials /ID# 259205

    Brandon, Florida · Active not recruiting

  • Florida Academic Dermatology Center /ID# 259353

    Coral Gables, Florida · Active not recruiting

  • Skin Research Institute LLC /ID# 259207

    Coral Gables, Florida · Completed

  • Revival Research /ID# 259213

    Doral, Florida · Completed

  • Skin Care Research - Hollywood /ID# 259210

    Hollywood, Florida · Recruiting

  • GSI Clinical Research, LLC /ID# 259352

    Margate, Florida · Recruiting

  • Life Clinical Trials - N State Rd - Margate /ID# 259358

    Margate, Florida · Active not recruiting

  • Lenus Research and Medical Group /ID# 259356

    Miami, Florida · Recruiting

  • International Clinical Research - Sanford /ID# 259547

    Sanford, Florida · Completed

  • FWD Clinical Research /ID# 266687

    Tamarac, Florida · Completed

  • Advanced Clinical Research Institute - Tampa /ID# 259204

    Tampa, Florida · Recruiting

  • Avita Clinical Research /ID# 258011

    Tampa, Florida · Completed

  • Cleaver Medical Group Dermatology /ID# 259801

    Dawsonville, Georgia · Active not recruiting

  • Marietta Dermatology /ID# 259818

    Marietta, Georgia · Active not recruiting

  • Northwestern Medicine - Northwestern Memorial Hospital /ID# 259555

    Chicago, Illinois · Completed

  • NorthShore University HealthSystem - Skokie /ID# 266684

    Skokie, Illinois · Active not recruiting

  • Indiana University Health University Hospital /ID# 259827

    Indianapolis, Indiana · Recruiting

  • U.S. Dermatology Partners Leawood /ID# 259203

    Leawood, Kansas · Completed

  • Tulane University School of Medicine /ID# 259799

    New Orleans, Louisiana · Recruiting

  • Raven Clinical Research /ID# 268453

    Marriottsville, Maryland · Completed

  • MetroBoston Clinical Partners /ID# 259559

    Boston, Massachusetts · Active not recruiting

  • Lahey Hospital and Medical Center /ID# 260484

    Burlington, Massachusetts · Completed

  • Great Lakes Research Group - Bay City /ID# 259100

    Bay City, Michigan · Completed

  • Derm Institute of West Michigan /ID# 259546

    Caledonia, Michigan · Recruiting

  • Hamzavi Dermatology - Canton /ID# 260115

    Canton, Michigan · Completed

  • Clarkston Dermatology /ID# 258018

    Clarkston, Michigan · Recruiting

Showing 40 of 272 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.